Target intelligence / Profile preview

Burkholderia pseudomallei antigens (B. pseudomallei antigens)

Target
B. pseudomallei antigens
Molecular classification
Bacterial antigen, Polysaccharide, Protein, Virulence factor
01

Overview

Burkholderia pseudomallei antigens are a collection of surface-exposed and secreted molecules that play critical roles in the pathogenesis of melioidosis, a severe infectious disease (Wiersinga et al., Nature Reviews Microbiology, 2012). Key antigens include the Type I capsular polysaccharide (CPS), which is vital for resisting complement-mediated killing, and the Type II lipopolysaccharide (LPS), which contributes to the inflammatory response (Titball et al., Frontiers in Immunology, 2017). Additionally, proteins such as Hcp1 (Type VI secretion system) and BipD (Type III secretion system) are essential for the bacterium's ability to invade host cells and escape endosomes (Limmathurotsakul et al., Journal of Clinical Microbiology, 2011). These antigens are primary targets for the development of vaccines and monoclonal antibodies, as they can elicit protective immune responses that facilitate bacterial clearance. Because B. pseudomallei is a Tier 1 select agent with high antibiotic resistance, targeting these antigens is a major focus for biodefense and public health research.

Other names
Melioidosis antigensB. pseudomallei surface antigensB. pseudomallei virulence factors
02

Mechanism of action

Induction of opsonophagocytic antibodies; neutralization of bacterial secretion systems; inhibition of host cell attachment and invasion; passive immunization via monoclonal antibodies.

03

Biological functions

Bacterial virulenceImmune evasionHost cell invasionProtein secretionIntracellular survival
04

Disease associations

InfectionSepsisMelioidosis
05

Safety considerations

Potential for cross-reactivity with host glycansRisk of incomplete protection leading to chronic carriage or latencyChallenges in achieving sterile immunity against intracellular reservoirsStrain-specific variability in antigen expression
06

Interacting drugs

CPS-CRM197 (Experimental conjugate vaccine)

4 more in the full profile.

07

Biomarkers

Anti-capsular polysaccharide (CPS) IgG antibody titersAnti-hemolysin-coregulated protein 1 (Hcp1) antibody levelsAnti-lipopolysaccharide (LPS) antibody levels

Beyond the preview

Go deeper on Burkholderia pseudomallei antigens (B. pseudomallei antigens).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Burkholderia pseudomallei antigens (B. pseudomallei antigens).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call